Search results
Results from the WOW.Com Content Network
A DEA number (DEA Registration Number) is an identifier assigned to a health care provider (such as a physician, physician assistant, nurse practitioner, optometrist, podiatrist, dentist, or veterinarian) by the United States Drug Enforcement Administration allowing them to write prescriptions for controlled substances.
On December 10, 2004, however, following a lawsuit filed over unreasonable delay in responding to the application, [105] the DEA rejected Craker's application. [106] Professor Craker then filed another lawsuit in response to the rejection, and also requested a hearing on the matter from a DEA Administrative Law Judge, which was granted. [24]
Research on the medical benefits of cannabis has been hindered by various federal regulations, including its Schedule I classification. [3] To conduct research on cannabis, approval must be obtained from the Food and Drug Administration, [4] and a license must be obtained from the Drug Enforcement Administration specific to Schedule I drugs. [5]
The Drug Enforcement Administration was established on July 1, 1973, [4] by Reorganization Plan No. 2 of 1973, signed by President Richard Nixon on July 28. [5] It proposed the creation of a single federal agency to enforce the federal drug laws as well as consolidate and coordinate the government's drug control activities.
DEA has agreed to extend the enforcement flexibility allowing non-DEA registered labs to test hemp until January 1, 2022, and is processing lab registration applications quickly to get more labs testing hemp DEA-registered. [8] Timing of sample collection – the IFR stated a 15-day window to collect samples before harvest.
Get AOL Mail for FREE! Manage your email like never before with travel, photo & document views. Personalize your inbox with themes & tabs. You've Got Mail!
John Ingersoll was the first Director of the BNDD, being appointed on August 1, 1968, and its last. He departed the bureau in disgruntlement on June 29, 1973, and the bureau was merged into the new DEA two days later.
On October 18, 1985, the DEA issued a Notice of Proposed Rulemaking to transfer "Synthetic Dronabinol in Sesame Oil and Encapsulated in Soft Gelatin Capsules" — a pill form of Δ 9-tetrahydrocannabinol, the main psychoactive component of cannabis, sold under the brand name Marinol — from Schedule I to Schedule II (DEA 50 FR 42186-87).